Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia

British Journal of Urology

Volumn 82, Issue 3, 1998, Pages 380-385

  Colombel, M ^a   Vacherot, F ^b   Gil Diez, S ^c   Fontaine, E ^d   Buttyan, R ^a   Chopin, D ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c Och Spine at New York Presbyterian Hospitals

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Apoptosis; Bcl 2; Cell cycle; Cell division; Prostate; Prostatic hyperplasia

Indexed keywords

PROTEIN BCL 2;

ADULT; APOPTOSIS; ARTICLE; CELL COMPARTMENTALIZATION; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA NICK TRANSLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

ADULT; APOPTOSIS; CELL DIVISION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATIC HYPERPLASIA; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0031696396     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00752.x     Document Type: Article

References (29)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984: 132: 474-9
2. McNeal JE. Origin and evolution of benign prostatic enlargement. Inv Urol 1978: 15: 341-4
3. Peters C. Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplusia. New Eng Med }1987: 318: 599-604
4. Lepor H. Role of long acting selective alpha l blockers in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990: 17: 651-60
5. Trachenberg J, Hicks LL. Walsh PC. Androgen and estrogen receptor content in spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 1980: 63: 180-6
6. Barrack ER. Berry SJ. DNA synthesis in the benign prostate: effect of androgen and estrogen treatment. Prostate 1987; 10: 45-56
7. Dermer GB. Basal cell proliferation in benign prostatic hyperplasia. Cancer 1978: 41: 1857-62
8. Kyprianou N. Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988: 552: 562-5
9. Gatzner H. Monoclonal antibody to 5-bromo and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science (Washington DC) 1984: 218: 474-5
10. Takasaki J, Fishwild D, Tan EM. Characterization of proliferating cell nuclear antigen recognized by auto antibody in lupus sera. J Exp Med 1984: 159: 981-92
11. Wijsman JH, Jonker RR, Keijer R, Van der velse CJH. Cornelisse CJ. Van Dierendock JH. A new method to detect apoptosis in paraffin sections: in situ end labeling of fragmented DNA. J Histochern 1993: 41: 7-12
12. Colombel M. Radvanyi F, Blanche M et al. Androgen suppressed apoptosis is modified in p55 deficient mice. Oncogene 1995: 10: 1269-74
13. Colombel M. Symmans F. Gil S et al. Detection of the apoptosis suppressing oncoprotein hc!2 in hormone refractory cancer. Am J Pathol 1993: 143: 390-400
14. McNeal JE. Normal histology of the prostate. Am }Surg Pathol 1988; 12: 619-33
15. Colombel M, Olsson CA. Ng PY, Buttyan R. Hormone regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 1992; 52: 4313-9
16. Chang S. Chung LWK. Interaction between prostatic libroblast and epithelial cells in culture: role of androgen. Endocrinology 1989: 125: 2719-27
17. Djakiew D, Tarkington MA. Lynch JH. Paracrine stimulation of polarized secretion from monolayers of a neoplastic prostatic epithelial cell line by prostatic stromal cell proteins. Cancer Res 1990; 50: 1966-74
18. Camps JL, Chang SM, Hsu TC et al. Fibroblast-mediated acceleration of epithelial tumor growth in vivo. Proc Natl AcadSci USA 1990: 87: 75-9
19. Sikes RA. Thomsen S, Petrow V, Neubauer BL, Chung LWK. Inhibition of experimentally induced mouse prostatic hyperplasia by castration or steroid antagonist administration. Rial Reprod 1990: 43: 353-62
20. Freeman MR. Song Y. Carson I)D, Guthrie I'D, Chung LWK. Extracellular matrix and androgen receptor expression associated with spontaneous transformation of rat prostate fihroblasts. Cancer Res 1991; 51: 1910-6
21. Steiner G. Gessl A, Kramer G. Schochammer A, Forster 0. Marberger M. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Ural 1994; 151: 480-4
22. Aihara M. Scardino PT, Truong Lu et al The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer 1995: 75: 522-9
23. Hockenbery D. Nunez G. Milliman C. Schreiber RD. Korsmeyer SJ. Bcl2 is an inner mitochondria! membrane protein that blocks programmed cell death. Nature 1990; 358: 334-6
24. McDonnel TJ. Deane N. Platt FM et al. Bcl2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989: 57: 79-88
25. Zhang W, Chen MW. Ng PY, Olsson CA. Buttyan R. Hyperproliferative prostate epithelium and stroma induced in c3-bcl-2 tissue specific transgenic mice. J Urol 1996: 156: l 378A
26. Raffo AJ. Perlman H. Chen MW, Pay ML. Steitman JS. Buttyan R. Overexpression of bc!2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-45
27. Cardillo M. Berchem G. Tarkington MA et al. Resistance to apoptosis and up-regulation in benign prostatic hyperplasia after androgen deprivation. J Urol 1997; 158: 212-6
28. Claus S. Berges R. Senge T, Schulze H. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia. J Urol 1997; 158: 217-21
29. Djonov V, Ball RV. Studer UR, Merz V. Transforming growth factors B 3 expression correlates with cytoplasmic localization of the androgen receptor and with cell death in normal prostate end benign prostatic hyperplasia. J Urol 1996; 56: l 394A